Nothing Special   »   [go: up one dir, main page]

WO2003024483A1 - Potentiator for inhibitory effects on urinary frequency and urinary incontinence - Google Patents

Potentiator for inhibitory effects on urinary frequency and urinary incontinence Download PDF

Info

Publication number
WO2003024483A1
WO2003024483A1 PCT/JP2002/009178 JP0209178W WO03024483A1 WO 2003024483 A1 WO2003024483 A1 WO 2003024483A1 JP 0209178 W JP0209178 W JP 0209178W WO 03024483 A1 WO03024483 A1 WO 03024483A1
Authority
WO
WIPO (PCT)
Prior art keywords
urinary
frequency
potentiator
urinary incontinence
inhibitory effects
Prior art date
Application number
PCT/JP2002/009178
Other languages
French (fr)
Japanese (ja)
Inventor
Yutaka Kono
Kaori Hamada
Nobuhiro Yamamoto
Shintaro Miura
Takao Yamamoto
Naoko Unami
Keiko Nakano
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Publication of WO2003024483A1 publication Critical patent/WO2003024483A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)

Abstract

As remedies for urinary frequency and urinary incontinence, use has been mainly made of cholinolytics having a cholinolytic effect such as oxybutynin hydrochloride. However, sufficient effects cannot be achieved in some cases even by using these cholinolytics. Thus it has been required to develop a remedy for urinary frequency and urinary incontinence whereby the effect of the cholinolytics can be potentiated. A potentiator for inhibitory effects on urinary frequency and urinary incontinence comprising a compound having a β3 agonist activating effect which is known as a useful remedy for urinary frequency and urinary incontinence.
PCT/JP2002/009178 2001-09-11 2002-09-09 Potentiator for inhibitory effects on urinary frequency and urinary incontinence WO2003024483A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001274868 2001-09-11
JP2001-274868 2001-09-11

Publications (1)

Publication Number Publication Date
WO2003024483A1 true WO2003024483A1 (en) 2003-03-27

Family

ID=19099832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/009178 WO2003024483A1 (en) 2001-09-11 2002-09-09 Potentiator for inhibitory effects on urinary frequency and urinary incontinence

Country Status (1)

Country Link
WO (1) WO2003024483A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018773A1 (en) * 2010-08-03 2012-02-09 Altherx, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
JP2013507363A (en) * 2009-10-07 2013-03-04 メルク・シャープ・エンド・ドーム・コーポレイション Combination therapy with β3 adrenergic receptor agonist and antimuscarinic agent
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455006A2 (en) * 1990-05-04 1991-11-06 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
WO1994018161A1 (en) * 1993-02-09 1994-08-18 Merck & Co., Inc. SUBSTITUTED PHENYL SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
JPH07228543A (en) * 1994-02-16 1995-08-29 Fujisawa Pharmaceut Co Ltd New pharmaceutical use of beta3-adrenalin agonist
EP0958835A1 (en) * 1996-08-19 1999-11-24 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
WO2000012462A1 (en) * 1998-08-26 2000-03-09 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455006A2 (en) * 1990-05-04 1991-11-06 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
WO1994018161A1 (en) * 1993-02-09 1994-08-18 Merck & Co., Inc. SUBSTITUTED PHENYL SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
JPH07228543A (en) * 1994-02-16 1995-08-29 Fujisawa Pharmaceut Co Ltd New pharmaceutical use of beta3-adrenalin agonist
EP0958835A1 (en) * 1996-08-19 1999-11-24 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
WO2000012462A1 (en) * 1998-08-26 2000-03-09 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2485595A4 (en) * 2009-10-07 2014-03-12 Merck Sharp & Dohme Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
JP2013507363A (en) * 2009-10-07 2013-03-04 メルク・シャープ・エンド・ドーム・コーポレイション Combination therapy with β3 adrenergic receptor agonist and antimuscarinic agent
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
AU2011285928B9 (en) * 2010-08-03 2018-08-02 B3Ar Therapeutics, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
JP2013535486A (en) * 2010-08-03 2013-09-12 アルセレックス，インコーポレイテッド Combination of β-3 adrenergic receptor agonist and muscarinic receptor antagonist for the treatment of overactive bladder
AU2011285928B2 (en) * 2010-08-03 2016-06-16 B3Ar Therapeutics, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
JP2017002074A (en) * 2010-08-03 2017-01-05 ヴェリセプト テラピューティクス，インコーポレイテッド COMBINATIONS OF β-3 ADRENERGIC RECEPTOR AGONISTS AND MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATING OVERACTIVE BLADDER
WO2012018773A1 (en) * 2010-08-03 2012-02-09 Altherx, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US10668034B2 (en) 2010-08-03 2020-06-02 Velicept Therapeutcis, Inc. Pharmaceutical compositions and the treatment of overactive bladder
EA030145B1 (en) * 2010-08-03 2018-06-29 Велисепт Терапьютикс, Инк. Combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US8642661B2 (en) 2010-08-03 2014-02-04 Altherx, Inc. Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists
US10350182B2 (en) 2010-08-03 2019-07-16 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
US10751311B2 (en) 2014-12-03 2020-08-25 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
US10221126B2 (en) 2015-10-23 2019-03-05 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
US10844004B2 (en) 2015-10-23 2020-11-24 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
US11691944B2 (en) 2015-10-23 2023-07-04 B3Ar Therapeutics, Inc. Solabegron zwitterion and uses thereof

Similar Documents

Publication Publication Date Title
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2006081276A8 (en) 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
EP1859793A4 (en) Novel combinational use of sulfonamide compound
WO2005117872A3 (en) Dual acting snri-nmda antagonists for the treatment of genitourinary disorders
WO2006089023A3 (en) Pharmaceutical compositions for treating or preventing bone conditions
AU2002354056A1 (en) Remedies for urinary frequency
EP1894564A3 (en) Use of an ibat inhibitor for the treatment of prophylaxis of constipation
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
AU2001244399A1 (en) Gamma-secretase inhibitors
WO2005087724A3 (en) Sulphonylpyrroles as hdac inhibitors
WO2006127941A3 (en) Amorphous cinacalcet hydrochloride and preparation thereof
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
WO2006132959A3 (en) Inhibition of thrombin generation
WO2007033163A3 (en) Broadband transmission line transformer
WO2005115370A3 (en) Compounds and methods for treating non-inflammatory pain using pparalpha agonists
WO2006009718A3 (en) Methods for treating or preventing erectile dysfunction or urinary incontinence
WO2006057997A3 (en) Plasmin-inhibitory therapies
WO2007059226A3 (en) Photoactivatable antimicrobial agents
AU2002228317A1 (en) Benz-1,3-azole derivatives and their uses as heparanase inhibitors
WO2001056573A8 (en) Use of cox-2 inhibitors as gastroprokinetics
WO2002037927A3 (en) Compounds and methods for promoting smoking cessation
WO2006029398A8 (en) All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use
EP1905436A4 (en) Synergistic time-delaying agent for local anestheic
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
WO2003024483A1 (en) Potentiator for inhibitory effects on urinary frequency and urinary incontinence

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP